<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName journalpublishing.dtd?>
  <?SourceDTD.Version 2.3?>
  <?ConverterInfo.XSLTName jp2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Front Synaptic Neurosci</journal-id>
      <journal-id journal-id-type="publisher-id">Front. Syn. Neurosci.</journal-id>
      <journal-title-group>
        <journal-title>Frontiers in Synaptic Neuroscience</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1663-3563</issn>
      <publisher>
        <publisher-name>Frontiers Research Foundation</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3099362</article-id>
      <article-id pub-id-type="pmid">21629767</article-id>
      <article-id pub-id-type="doi">10.3389/fnsyn.2011.00003</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Neuroscience</subject>
          <subj-group>
            <subject>Original Research</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Blocking Effects of Human Tau on Squid Giant Synapse Transmission and Its Prevention by T-817 MA</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Moreno</surname>
            <given-names>Herman</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Choi</surname>
            <given-names>Soonwook</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>Eunah</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brusco</surname>
            <given-names>Janaina</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Avila</surname>
            <given-names>Jesus</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moreira</surname>
            <given-names>Jorge E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sugimori</surname>
            <given-names>Mutsuyuki</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Llin&#xE1;s</surname>
            <given-names>Rodolfo R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn001">*</xref>
          <xref ref-type="author-notes" rid="fn002">
            <sup>&#x2020;</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <sup>1</sup>
        <institution>Departments of Neurology and Physiology/Pharmacology, The Robert F. Furchgott Center for Neural and Behavioral Science, SUNY Downstate Medical Center</institution>
        <country>Brooklyn, NY, USA</country>
      </aff>
      <aff id="aff2">
        <sup>2</sup>
        <institution>Marine Biological Laboratory</institution>
        <country>Woods Hole, MA, USA</country>
      </aff>
      <aff id="aff3">
        <sup>3</sup>
        <institution>Department of Physiology and Neuroscience, New York University School of Medicine</institution>
        <country>New York, NY, USA</country>
      </aff>
      <aff id="aff4">
        <sup>4</sup>
        <institution>Department of Cell and Molecular Biology, Riber&#xE3;o Preto School of Medicine, University of S&#xE3;o Paulo</institution>
        <country>Ribeir&#xE3;o Preto, Brazil</country>
      </aff>
      <aff id="aff5">
        <sup>5</sup>
        <institution>Centro de Biolog&#xED;a Molecular &#x201C;Severo Ochoa&#x201D;, Universidad Aut&#xF3;noma de Madrid</institution>
        <country>Madrid, Spain</country>
      </aff>
      <author-notes>
        <fn fn-type="edited-by">
          <p>Edited by: Jo&#xEB;l Bockaert, INSERM, France</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Reviewed by: Carlo Sala, CNR Institute of Neuroscience, Italy; Jo&#xEB;l Bockaert, INSERM, France</p>
        </fn>
        <corresp id="fn001">*Correspondence: Rodolfo R. Llin&#xE1;s, Department of Physiology and Neuroscience, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA. e-mail: <email>llinar01@med.nyu.edu</email></corresp>
        <fn fn-type="other" id="fn002">
          <p><sup>&#x2020;</sup>Contributed by Rodolfo R. Llin&#xE1;s.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epreprint">
        <day>04</day>
        <month>4</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <volume>3</volume>
      <elocation-id>3</elocation-id>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>1</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>5</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2011 Moreno, Choi, Yu, Brusco, Avila, Moreira, Sugimori and Llin&#xE1;s.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license license-type="open-access" xlink:href="http://www.frontiersin.org/licenseagreement">
          <license-p>This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Filamentous tau inclusions are hallmarks of Alzheimer's disease and related neurodegenerative tauopathies, but the molecular mechanisms involved in tau-mediated changes in neuronal function and their possible effects on synaptic transmission are unknown. We have evaluated the effects of human tau protein injected directly into the presynaptic terminal axon of the squid giant synapse, which affords functional, structural, and biochemical analysis of its action on the synaptic release process. Indeed, we have found that at physiological concentration recombinant human tau (h-tau42) becomes phosphorylated, produces a rapid synaptic transmission block, and induces the formation of clusters of aggregated synaptic vesicles in the vicinity of the active zone. Presynaptic voltage clamp recordings demonstrate that h-tau42 does not modify the presynaptic calcium current amplitude or kinetics. Analysis of synaptic noise at the post-synaptic axon following presynaptic h-tau42 microinjection revealed an initial phase of increase spontaneous transmitter release followed by a marked reduction in noise. Finally, systemic administration of T-817MA, a proposed neuro-protective agent, rescued tau-induced synaptic abnormalities. Our results show novel mechanisms of h-tau42 mediated synaptic transmission failure and identify a potential therapeutic agent to treat tau-related neurotoxicity.</p>
      </abstract>
      <kwd-group>
        <kwd>tauopathies</kwd>
        <kwd>synaptic transmission</kwd>
        <kwd>hyperphosphorylation</kwd>
        <kwd>Altzheimer's disease</kwd>
        <kwd>neurodegenerative</kwd>
        <kwd>human tau</kwd>
        <kwd>synaptic vesicles</kwd>
        <kwd>neuro-protective agent</kwd>
      </kwd-group>
      <counts>
        <fig-count count="4"/>
        <table-count count="1"/>
        <equation-count count="0"/>
        <ref-count count="37"/>
        <page-count count="8"/>
        <word-count count="6430"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="introduction">
      <title>Introduction</title>
      <p>Classical neuropathological studies characterized the intracellular accumulation and aggregation of abnormal filaments composed primarily of the microtubule associated protein tau as a hallmark for a variety of neurodegenerative disorders known as tauopathies, as exemplified by progressive supranuclear palsy, Pick's disease, corticobasal degeneration, and frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17; Lee et al., <xref ref-type="bibr" rid="B17">2001</xref>). The most common tauopathy, Alzheimer's disease (AD), is also characterized by additional filamentous structures paired helical filaments (PHFs) and straight filaments (SFs). These filaments eventually form large aggregations, known as neurofibrillary tangles (NFTs). In addition, diffuse and mature senile plaques, which are predominantly composed of amyloid beta (A&#x3B2;) peptides, are present in AD brains too (Selkoe, <xref ref-type="bibr" rid="B32">2001</xref>).</p>
      <p>A number of studies have investigated the role of different forms of A&#x3B2; peptides and aggregates in synaptic function (Arancio et al., <xref ref-type="bibr" rid="B1">2004</xref>; Moreno et al., <xref ref-type="bibr" rid="B24">2009</xref>), but so far the role of tau or tau aggregates in neurotransmission has not been elucidated.</p>
      <p>The association between tau filaments, neuron loss, and brain dysfunction in vertebrates and invertebrates originally led to the hypothesis that NFTs invariably cause brain dysfunction and neurodegeneration. However, mouse tauopathy studies indicate that severe abnormalities in synaptic function can precede neuronal loss and even NFTs formation (LaFerla et al., <xref ref-type="bibr" rid="B14">2007</xref>; Yoshiyama et al., <xref ref-type="bibr" rid="B37">2007</xref>). While the molecular mechanisms responsible for this early malfunction (as well as those responsible for tau polymerization dependent pathogenesis) remain unknown (Marx, <xref ref-type="bibr" rid="B22">2007</xref>). Neurofibrillary degeneration is accompanied by lysosomal hypertrophy (Nixon et al., <xref ref-type="bibr" rid="B28">1992</xref>), beading and degeneration of distal dendrites (Braak et al., <xref ref-type="bibr" rid="B4">1994</xref>; Marx, <xref ref-type="bibr" rid="B22">2007</xref>) and axonal damage (Kowall and Kosik, <xref ref-type="bibr" rid="B13">1987</xref>).</p>
      <p>In the present study physiological concentrations of recombinant human tau isoform (full length h-tau42; Perez et al., <xref ref-type="bibr" rid="B29">2001</xref>) was directly injected into the presynaptic terminal of the squid giant synapse, to examine possible acute effects of h-tau on the synaptic release mechanism. The results showed that heavy exogenous h-tau42 accumulation induces a rapid and short-lasting increase in spontaneous transmitter release followed by a drastic decrease and failure of synaptic transmission. This synaptic block does not affect presynaptic calcium current flow or spike generation at the presynaptic terminal. Immunohistochemistry, performed in h-tau42 injected synapses, demonstrated that h-tau42 becomes phosphorylated rapidly in good temporal agreement with the time course of the transmitter failure. Electron microscopy and electrophysiological experiments unambiguously indicate that h-tau42-mediated synaptic transmission block is due to exocytosis failure. Finally, systemic administration of the novel compound T-817MA prevented the structural, biochemical, and functional deleterious effects h-tau42 microinjection.</p>
      <p>The present set of studies identifies several mechanisms of tau-mediated toxicity at the presynaptic terminal, and introduces a potential disease modifier for AD and other tauopathies for which there is no specific treatment presently.</p>
    </sec>
    <sec sec-type="materials|methods" id="s1">
      <title>Materials and Methods</title>
      <sec>
        <title>Tau proteins</title>
        <p>Recombinant human tau, h-tau42 (isoform with four tubulin binding motifs and two extra exons in the N-terminal domain) was isolated as previously described (Perez et al., <xref ref-type="bibr" rid="B29">2001</xref>).</p>
      </sec>
      <sec>
        <title>Immunohistochemistry</title>
        <p>A variation of the array tomography method by Micheva and Smith (<xref ref-type="bibr" rid="B23">2007</xref>) was followed. The ganglia were fixed by immersion in 4% paraformaldehyde (EM grade EM Sciences) plus 7.0% sucrose in calcium-free sea water for 3&#x2009;h; rinsed with 7 % sucrose and 50&#x2009;mM glycine in 0.1&#x2009;M PBS; dehydrated with graded ethanol dilutions (50%, 70%, 90%, and 3&#xD7; 100%), embedded in LR White resin (medium grade, SPI), and polymerized in gelatin capsules at 49&#xB0;C for 48&#x2009;h. Semithin sections (500&#x2009;nm) were mounted on subbed slides and encircled on the slides with a PAP pen (EM Sciences, USA). The immunocytochemistry was done as follows: (a) blocked in 50&#x2009;mM glycine in tris buffer pH 7.6, 5&#x2009;min; (b) primary antibody incubation, anti-tau PHF (AT8, Thermoscientific, USA) diluted 1:50 in 1% BSA in tris (tris-BSA), 4&#x2009;h; (c) rinses in tris-BSA 2&#xD7; 5&#x2009;min: (d) secondary antibody incubation, goat anti-mouse Alexa Fluor 594 diluted 1:150 in tris-BSA, 30&#x2009;min; (e) tris and distilled water rinses, 4&#xD7; 5&#x2009;min each; (f) mounting of slides with coverslips and anti-fading mounting media; (g) image under fluorescent microscopy (Zeiss Axioimager, Germany). Controls were performed with the same protocol omitting the primary antibody. Primary antibody: Anti-tau PHF (AT8; Thermoscientific, USA), secondary antibody: Alexa Fluor 594 goat anti-mouse (Invitrogen).</p>
      </sec>
      <sec>
        <title>T-817MA administration</title>
        <p>Squid received an oral dose of T-817MA (0.25&#x2009;ml of 3.68&#x2009;mmol&#x2009;l<sup>&#x2212;1</sup> T-817AM) every 12&#x2009;h using a methodology recently developed by our group (Berk et al., <xref ref-type="bibr" rid="B3">2009</xref>). At 24&#x2009;h after the first dose a second dose was given, and the electrophysiological experiments were performed 1&#x2009;h after the second feeding. The optimal dose, absorption, and concentration reached in the optic lobes of T-817MA in squid had been obtained previously (Berk et al., <xref ref-type="bibr" rid="B3">2009</xref>). Indeed, it was determine that after 24&#x2009;h of the double administration, a T817-MA concentration of 26.7&#x2009;&#x3BC;mol&#x2009;1<sup>&#x2212;1</sup> was measured in the CNS of the gastrically intubated squid (<italic>n</italic>&#x2009;=&#x2009;10 squid). Synapses from T-817MA-treated squid were microinjected at the presynaptic axon with h-tau42 (an approximate 80&#x2009;nM final concentration h-tau42 (<italic>n</italic>&#x2009;=&#x2009;19), considering a 100&#xD7; dilution factor. Pre- and post-synaptic potentials were recorded for 90&#x2009;min.</p>
      </sec>
      <sec>
        <title>Electrophysiology and microinjections</title>
        <p>The squid (<italic>Loligo paelli</italic>) stellate ganglia isolation from the mantle and the electrophysiological techniques used have been described previously (Llinas et al., <xref ref-type="bibr" rid="B20">1985</xref>). Two glass micropipette electrodes impaled the largest (most distal) presynaptic terminal digit at the synaptic junction site while the post-synaptic axon was impaled by one microelectrode at the junctional site. One of the pre-electrodes was used for pressure microinjection of h-Tau 42 and also supported voltage clamp current feedback, while the second monitored membrane potential. The total volume injected fluctuated between 0.1 and 1&#x2009;pl. (Llinas et al., <xref ref-type="bibr" rid="B20">1985</xref>). The exact location of injection and the diffusion and steady-state distribution of the protein/fluorescent dye mix (0.001% dextran fluorescein) were monitored using a fluorescence microscope attached to a Hamamatsu camera system (Middlesex, NJ). In all experiments a good correlation was observed between the localization of the fluorescence and the electrophysiological findings.</p>
      </sec>
      <sec>
        <title>Electron microscopy</title>
        <p>Immediately following the electrophysiological study the ganglia were removed from the recording chamber, fixed by immersion in glutaraldehyde, post-fixed in osmium tetroxide, stained in block with uranium acetate, dehydrated and embedded in resin (Embed 812, EM Sciences). Ultrathin sections were collected on Pioloform (Ted Pella, Redding, CA) and carbon-coated single sloth grids, and contrasted with uranyl acetate and lead citrate. Morphometry and quantitative analysis of the synaptic vesicles were performed with the in house program developed with LabVIEW (National Instruments, Ostin, TX, USA). Electron micrographs were taken at an initial magnification of &#xD7;16,000 and &#xD7;31,500 and photographically enlarged to a magnification of &#xD7;40,000 and &#xD7;79,000 for synaptic vesicles and clathrin-coated vesicle (CCV) counting, respectively. Vesicle density at the synaptic active zones was determined as the number of vesicles per &#x3BC;m<sup>2</sup>, on an average area of 0.8&#x2009;&#x3BC;m<sup>2</sup> per active zone. CCV density was determined within the limits of the presynaptic terminal on an average terminal area of 3.3&#x2009;&#x3BC;m<sup>2</sup>.</p>
      </sec>
      <sec>
        <title>Pharmacological tools</title>
        <p>T-817MA (1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}azetidin-3-ol maleate), was synthesized at Toyama Chemical Co. Ltd., Japan.</p>
      </sec>
    </sec>
    <sec>
      <title>Results</title>
      <sec>
        <title>Intra-axonal h-tau42 acutely blocks synaptic transmission</title>
        <p>Following presynaptic and post-synaptic axon impalements and the determination of normal synaptic transmission (Llinas et al., <xref ref-type="bibr" rid="B20">1985</xref>, <xref ref-type="bibr" rid="B21">1994</xref>; Lin et al., <xref ref-type="bibr" rid="B18">1990</xref>), the effect of human tau on synaptic release was evaluated by presynaptic microinjections administered under direct visualization using a fluorescent dye/protein mix, reaching a final concentration after diffusion of approximately 80&#x2009;nM (see <xref ref-type="sec" rid="s1">Materials and Methods</xref>). Presynaptic and post-synaptic potentials were recorded simultaneously under current-clamp configuration. Presynaptic spikes were activated every 5&#x2009;min (low-frequency protocol). With this paradigm, it was determined that 5&#x2013;10&#x2009;min after an injection of h-tau42, a reduction of transmitter release could be observed. With further time, a total block of transmission resulted, within 30&#x2013;40&#x2009;min depending on the length of the release zone in the preterminal axon (Figures <xref ref-type="fig" rid="F1">1</xref>A and <xref ref-type="fig" rid="F2">2</xref> blue dots, <italic>n</italic>&#x2009;=&#x2009;8). No modification of presynaptic spike amplitude or duration ensued (Figure <xref ref-type="fig" rid="F1">1</xref>A). By&#x2009;contrast, following T-817MA administration to the squid (see bellow) h-tau42-dependent transmitter block was prevented (Figures <xref ref-type="fig" rid="F1">1</xref>B and <xref ref-type="fig" rid="F2">2</xref> red dots, <italic>n</italic>&#x2009;=&#x2009;7).</p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <p><bold>Electrophysiological Findings following presynaptic h-tau42 injection</bold>. <bold>(A)</bold> Pre- and post-synaptic potential following a direct electrical stimulation of the presynaptic axon. Synaptic transmission fails in 30&#x2009;min following h-tau42 preinjection (six subsequent stimuli at 5-min intervals). <bold>(B)</bold> Similar experiment as in <bold>(A)</bold> (24 subsequent stimulus are shown at 5-min interval) following h-tau42 injection in a T-817MA-treated squid. Transmission block does not occur within the 2-h period. <bold>(C)</bold> Repetitive stimulation at 100&#x2009;Hz following h-tau42 injection results in a step like decrease in post-synaptic response amplitude that slowly progresses (post 1,2,3) but shows small variation in amplitude during a given stimulus train. <bold>(D)</bold> Similar train stimulus paradigm produced reduction of transmitter release, which recuperated to the 80% amplitude in 15&#x2009;min (post 1, 2, and 3). <bold>(E)</bold> Power spectra of spontaneous post-synaptic noise. Noise recording at the post-synaptic terminal (upper and lower panels on the left) were taken at 1-min intervals following h-tau42preinjection. Spontaneous release as determined by synaptic noise power spectrum (right panel) in <bold>(E)</bold>, showed rapid reduction within a 12-min interval (reading taken at a 1/minrate). <bold>(F)</bold> h-tau42 preinjection produces block of presynatic release (c) without affecting presynaptic inward calcium current (b). Preterminal voltage step were repeated every minutes. For further detail see text and Figure <xref ref-type="fig" rid="F2">2</xref>.</p>
          </caption>
          <graphic xlink:href="fnsyn-03-00003-g001"/>
        </fig>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p><bold>Time course of synaptic transmission reduction following presynaptic Tau injection</bold>. Single spike transmission, (blue circles <italic>n</italic>&#x2009;=&#x2009;8), voltage clamp release (black circles, <italic>n</italic>&#x2009;=&#x2009;4), post-synaptic spectral noise (purple circles <italic>n</italic>&#x2009;=&#x2009;3) and repetitive presynaptic stimulation (brown circles <italic>n</italic>&#x2009;=&#x2009;3) resulted in a rapid reduction of transmitter release without recovery after 15-min rest period. Parenteral T-817MA administration results in the block of h-tau42 effect on transmitter release reduction (red circles <italic>n</italic>&#x2009;=&#x2009;7) and in the recovery of synaptic transmission from train stimulation after 15-min rest period.</p>
          </caption>
          <graphic xlink:href="fnsyn-03-00003-g002"/>
        </fig>
        <p>To determine whether the transmission block described above was produced by a reduction of transmitter availability (as would be expected by inhibition of any step in the synaptic vesicle recycling pathway, e.g., endocytosis, refilling of vesicles with transmitter, or docking.) or by a defect in synaptic vesicle fusion, the effect of trains of presynaptic high frequency stimuli (100&#x2009;Hz) was tested. This form of activation rapidly depleted the transmitter, as evidence by the rapid decrease in post-synaptic potential amplitude during a stimulus train (Figure <xref ref-type="fig" rid="F1">1</xref>D Post 2). The rapid time course of this decay has been shown to give an estimate of transmitter availability (Llin&#xE1;s et al., <xref ref-type="bibr" rid="B21">1994</xref>), and is a reflection of a decrease in either synaptic vesicle mobilization or docking. On the other hand, synaptic block accompanied by a slow, progressive reduction of post-synaptic amplitude, without amplitude reduction during the tetanic stimulus, is a direct indication that the block is due to a defect in transmitter release (Llin&#xE1;s et al., <xref ref-type="bibr" rid="B21">1994</xref>), i.e., vesicular fusion.</p>
        <p>The test paradigm implemented to address this query consisted of synaptic high frequency (100&#x2009;Hz) spike activation of the presynaptic axon of synapses preinjected with h-tau42 (Figure <xref ref-type="fig" rid="F1">1</xref>C, 1 Pre Figure <xref ref-type="fig" rid="F2">2</xref> light brown dots, <italic>n</italic>&#x2009;=&#x2009;4) which initially generated post-synaptic repetitive activation (Figure <xref ref-type="fig" rid="F1">1</xref>C, Post 1). This train stimulation was repeated once a minute until post-synaptic spike failure occurred from the first stimulus in the train. Note that the amplitude of the subthreshold synaptic potentials showed little reduction during the stimulus train itself but steadily reduced in amplitude as h-tau42 mobilizes into the preterminal. The fact that the amplitude of the evoked post-synaptic potentials remained unchanged during the duration of a given repetitive stimulation barrage indicates that the limiting factor was the vesicular release process (Figure <xref ref-type="fig" rid="F1">1</xref>C Post 2). This synaptic failure did not recuperate after 15&#x2009;min of rest (as normally occur in this preparation; Llinas et al., <xref ref-type="bibr" rid="B20">1985</xref>, <xref ref-type="bibr" rid="B21">1994</xref>; Lin et al., <xref ref-type="bibr" rid="B18">1990</xref>), but rather diminished to just noticeable amplitude (Post 3). In synapses from squid pretreated with T-817MA, microinjection with h-tau42 (Figures <xref ref-type="fig" rid="F1">1</xref>D and <xref ref-type="fig" rid="F2">2</xref>, green dots <italic>n</italic>&#x2009;=&#x2009; 6), show the normal reduction of the EPSP amplitude during the repetitive stimulus barrage, however, the treated animals showed normal recovery after a 15-min rest period. These findings indicate that T-817MA administration results in the normal recovery of synaptic transmission after high frequency stimulation, suggesting that the h-tau 42 effects could relate to vesicular availability and not to the actual vesicular release process (Figure <xref ref-type="fig" rid="F1">1</xref>D Post 3 and Figure <xref ref-type="fig" rid="F2">2</xref>, green dot, <italic>n</italic>&#x2009;=&#x2009;5).</p>
      </sec>
      <sec>
        <title>Tau modifies spontaneous neurotransmitter release and produces an early transient increase in intracellular calcium</title>
        <p>Beyond spike-initiated release, the possibility that h-tau42 may affect spontaneous transmitter release was directly evaluated using post-synaptic noise analysis. A detailed description of the technique has been published by our team (Lin et al., <xref ref-type="bibr" rid="B18">1990</xref>). In all preparations tested (<italic>n</italic>&#x2009;=&#x2009;6) the membrane noise recorded from the post-synaptic axon increased during the initial 5&#x2009;&#xB1;&#x2009;1&#x2009;min after presynaptic microinjection of h-tau42, this was followed by rapid noise level reduction in parallel with decreased amplitude of the evoked transmitted release. An example of the time course of noise level changes is illustrated in Figure <xref ref-type="fig" rid="F1">1</xref>E (left panel and Figure <xref ref-type="fig" rid="F2">2</xref> purple dots <italic>n</italic>&#x2009;=&#x2009;3). Note the biphasic changes in noise levels. A frequency spectrum of the membrane noise at different times after the h-tau42 injection is shown in Figure <xref ref-type="fig" rid="F1">1</xref>E (right panel). This pattern indicates that block by h-tau42 interferes with both spontaneous and evoked transmitter release.</p>
      </sec>
      <sec>
        <title>Mechanisms underlying tau-induced synaptic block</title>
        <p>Following the initial finding that transmission is rapidly blocked by h-tau42; the possibility that this block was associated with changes in presynaptic calcium currents (ICa<sup>2+</sup>) was tested. The amplitude and time course of ICa<sup>2+</sup> (Figure <xref ref-type="fig" rid="F1">1</xref>F) were directly determined by presynaptic voltage clamp steps, after blocking voltage dependent K<sup>+</sup> and Na<sup>+</sup> currents (<italic>n</italic>&#x2009;=&#x2009;6), as previously described (Llinas et al., <xref ref-type="bibr" rid="B20">1985</xref>). ICa<sup>2+</sup> amplitude and time course were determined at 5-min intervals over a period of 25&#x2009;min following presynaptic injection of h-tau42, 80&#x2009;nM.</p>
        <p>Voltage clamp experiments were implemented with presynaptic voltage steps that generated presynaptic inward calcium current and post-synaptic EPSPs. Following h-tau42 injection presynaptic voltage steps were repeated at 5&#x2009;min intervals (low-frequency stimuli), which resulted in a progressive reduction of post-synaptic response amplitude, to total failure, without a change in the amplitude or time course of the presynaptic ICa<sup>2+</sup> (Figure <xref ref-type="fig" rid="F1">1</xref>F). Under normal conditions this paradigm results in transmitter release that last, unaltered, for up to 2&#x2009;h, the maximum period utilized (Llinas et al., <xref ref-type="bibr" rid="B20">1985</xref>). The results show, therefore, that neither the time course nor the amplitudes of the presynaptic calcium currents were altered concomitantly with the transmitter release block induced by h-tau42 (Figures <xref ref-type="fig" rid="F1">1</xref>F and <xref ref-type="fig" rid="F2">2</xref>). The time course and number of electrophysiological experiments are summarized in Figure <xref ref-type="fig" rid="F2">2</xref>.</p>
      </sec>
      <sec>
        <title>Intra-axonal h-tau42 becomes phosphorylated and produces synaptic vesicle aggregation</title>
        <p>Since the aggregation of typical tau filaments is accompanied by the development of tau hyperphosphorylation, we investigated whether h-tau42 residues serine 202, threonine 205 and/or 231were phosphorylated in the squid synapse. We used AT8 antibodies, as commonly used in neuropathological studies (Goedert et al., <xref ref-type="bibr" rid="B6">1995</xref>). Here, we used immunohistochemistry in a variance of the array tomography technique (Micheva and Smith, <xref ref-type="bibr" rid="B23">2007</xref>); we found that single sections (500&#x2009;nm) allowed a clear view of the pre- and post-synaptic compartments (Figure <xref ref-type="fig" rid="F3">3</xref>A). Anti-phospho-tau immunohistochemistry was detected as dot-like profiles in the presynaptic compartment in h-tau42 injected synapses but drastically reduced in T-817 treated squid (Figure <xref ref-type="fig" rid="F3">3</xref>B lower panel). These were absent in synapses injected with vehicle (Figure <xref ref-type="fig" rid="F3">3</xref>D lower panel). This finding demonstrates that h-tau42 becomes phosphorylated in the squid axon.</p>
        <fig id="F3" position="float">
          <label>Figure 3</label>
          <caption>
            <p><bold>Presynaptic hyperphosphorylation immunohistochemistry</bold>. <bold>(A)</bold> Confocal image of the giant synapse showing the presynaptic terminal (Pre Terminal) and the post-synaptic axon (Post Terminal). The red line indicates plane of section for the images in <bold>(B)</bold>, <bold>(C)</bold>, and <bold>(D)</bold>. <bold>(B)</bold> Light microscopical image of the two cross-sected giant axons showing the pre- and post-synaptic axoplasmic cytosol. Upper left panel (green): section of the synapse showing the presynaptic terminal (dark). Lower left panel: Fluorescence immunohistochemistry using AT8 antibodies, demonstrating h-tau42 phosphorylation level (red). <bold>(C)</bold> Upper middle panel: Transected synapse in a T-817MA-treated squid (green). Lower middle panel: Immunohistochemistry demonstrating a highly reduced level of h-tau42 phosphorylation (red). <bold>(D)</bold> Upper right panel: Transected synapse, injected with vehicle, to serve as a control, using the same protocol as in <bold>(C)</bold>. Lower panel immunohistochemical absence of h-tau42 phosphorylation in the h-tau42 uninjected synapse.</p>
          </caption>
          <graphic xlink:href="fnsyn-03-00003-g003"/>
        </fig>
      </sec>
      <sec>
        <title>Ultrastructural presynaptic changes secondary to h-tau42 injection</title>
        <p>The structural changes that follow h-tau42 injection were addressed by rapidly fixing stellate ganglia (see <xref ref-type="sec" rid="s1">Materials and Methods</xref>) after high or low-frequency stimulation protocols. The material consisted of injected synapses (62 synaptic active zones from 10 different squid) and vehicle-injected synapses (control, 27 active zones in five synapses). The synapses were fixed &#x223C;75&#x2013;90&#x2009;min after h-tau42 injection and processed for ultrastructural microscopy (see <xref ref-type="sec" rid="s1">Materials and Methods</xref>). There was a statistically significant reduction in the number of &#x201C;docked vesicles&#x201D; in h-tau42-injected synapses compared to axons injected with vehicle (Table <xref ref-type="table" rid="T1">1</xref>). This reduction was not seen in T817MA-treated squid following h-tau42 injection (Table <xref ref-type="table" rid="T1">1</xref>).</p>
        <table-wrap id="T1" position="float">
          <label>Table 1</label>
          <caption>
            <p><bold>Quantification of preterminal docked vesicles in: control, h-tau42 injected and h-tau42 injected in T-817MA pretreated squid</bold>.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <td align="left" rowspan="1" colspan="1"/>
                <th align="left" rowspan="1" colspan="1">Undocked</th>
                <th align="left" rowspan="1" colspan="1">Clathrin-coated</th>
                <th align="left" rowspan="1" colspan="1">Docked</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Control</td>
                <td align="left" rowspan="1" colspan="1">67.3&#x2009;&#xB1;&#x2009;5.8</td>
                <td align="left" rowspan="1" colspan="1">3.2&#x2009;&#xB1;&#x2009;0.4</td>
                <td align="left" rowspan="1" colspan="1">10.1&#x2009;&#xB1;&#x2009;0.7</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">h-tau42</td>
                <td align="left" rowspan="1" colspan="1">61.2&#x2009;&#xB1;&#x2009;3.3</td>
                <td align="left" rowspan="1" colspan="1">4.3&#x2009;&#xB1;&#x2009;0.3</td>
                <td align="left" rowspan="1" colspan="1">5.8&#x2009;&#xB1;&#x2009;0.4*</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">T817-MA&#x2009;+&#x2009;h-tau42</td>
                <td align="left" rowspan="1" colspan="1">56.7&#x2009;&#xB1;&#x2009;3.5</td>
                <td align="left" rowspan="1" colspan="1">3.9&#x2009;&#xB1;&#x2009;0.4</td>
                <td align="left" rowspan="1" colspan="1">10.0&#x2009;&#xB1;&#x2009;0.6*</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p><italic>Number of vesicles in 1 &#x3BC;m<sup>2</sup> of active zone, Average&#x2009;</italic>&#xB1;<italic>&#x2009;SEM, *p&#x2009;&#x2009;0.001</italic>.</p>
          </table-wrap-foot>
        </table-wrap>
        <p>As shown in representative control synapses (Figure <xref ref-type="fig" rid="F4">4</xref>A), vesicles are normally present at the active zone, some in contact with the presynaptic terminal membrane (docked). By contrast, in h-tau42-injected synapses (Figure <xref ref-type="fig" rid="F4">4</xref>B) vesicles were often closely aggregated with electron dense material serving as a bonding matrix (red dot). Similar electron dense material was also observed around vesicles in contact with the active zone (red arrows). At a lower magnification (Figure <xref ref-type="fig" rid="F4">4</xref>C) a large number of aggregated vesicular profiles are evident in the vicinity of the active zone (red dots). In T-817MA administered squid, the synaptic morphology was quite similar to the vehicle-injected synapses (compare Figures <xref ref-type="fig" rid="F4">4</xref>A,D). Quantification of number of undocked, docked, and clathrin-coated vesicles (CCV) among the three groups (control, h-tau42 injected, and h-tau42 injected&#x2009;+&#x2009;T-817MA) is tabulated in Table <xref ref-type="table" rid="T1">1</xref>.</p>
        <fig id="F4" position="float">
          <label>Figure 4</label>
          <caption>
            <p><bold>Ultrastructure of the synaptic junction demonstrating differences in normal and h-tau42 injected synapses in untreated and T-817MA-treated squid</bold>. <bold>(A)</bold> Control synapse showing the typical presynaptic ultrastructure with synaptic vesicles grouped at the synaptic active zone (scale bar: 100&#x2009;nm). <bold>(B)</bold> Ultrastructure of ah-tau42 injected synapse showing a synaptic vesicle cluster congealed around electron dense material (red dot, scale bar: 100&#x2009;nm). <bold>(C)</bold> low magnification image of a h-tau42 injected synapse showing a large number of vesicular clusters as in the upper panel also marked with red dots (scale bar: 500&#x2009;nm). <bold>(D)</bold>: Ultrastructural image of a T-817MA-treated squid demonstrating normal synaptic morphology and properly docked vesicles at the presynaptic active zone (scale bar: 100&#x2009;nm).</p>
          </caption>
          <graphic xlink:href="fnsyn-03-00003-g004"/>
        </fig>
      </sec>
      <sec>
        <title>Systemic administration of t-817MA prevented tau-mediated synaptic block, synaptic vesicle aggregation, and decreased h-tau42 phosphorylation</title>
        <p>T-817MA&#x2009;(1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate) is a newly developed neuro-protective agent that prevents oxidative stress, nitric oxide-induced neurotoxicity, and acts as a neurotrophic factor (Hirata et al., <xref ref-type="bibr" rid="B10">2005</xref>). Although it has been shown that T-817MA administration may ameliorate amyloid beta related neuronal dysfunction (Nguyen et al., <xref ref-type="bibr" rid="B27">2007</xref>; Kimura et al., <xref ref-type="bibr" rid="B12">2009</xref>), its effect on tau related pathology is unknown. To study the potential effects of T-817MA on tau neuropathology, squids received an oral dose of T-817MA as described in the Section <xref ref-type="sec" rid="s1">&#x201C;Materials and Methods&#x201D;</xref>. Electrophysiologically, as shown in Figure <xref ref-type="fig" rid="F1">1</xref>B no significant changes in the amplitude or time course of the pre- or post-synaptic potentials were observed. Further, ultrastructural studies in synapses used for the electrophysiological experiments demonstrated the number of docked vesicles recovered to the normal range in h-tau42/T-817MA squid (31 active zones in six synapses; 10.0&#x2009;&#xB1;&#x2009;0.6) compared to control synapses (10.1&#x2009;&#xB1;&#x2009;0.7), with the presence of normal CCV profiles (3.9&#x2009;&#xB1;&#x2009;0.4). Also clear was a significant reduction, of electron dense vesicles clusters and electron dense active zones (see Table <xref ref-type="table" rid="T1">1</xref>; Figure <xref ref-type="fig" rid="F4">4</xref>). It is thus concluded that T-817MA prevented the h-tau42 dependent synaptic vesicle clustering, indicating a close relation between such morphology and the synaptic transmitter release block observed electrophysiologically. Finally squid pretreated with T-817MA showed a significantly reduced signal of intra-axonal h-tau42 phosphorylation, as detected by AT8 immunohistochemistry (Figure <xref ref-type="fig" rid="F3">3</xref>).</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>While the underlying pathogenic mechanisms of tau related neuronal abnormalities remain obscure, the acute effects of preterminal injection of h-tau42 presented here suggest that synaptic dysfunction is an early mechanism in AD and other tauopathies. We used the squid giant synapse in this study because it provides unique advantages in addressing the cellular and molecular mechanisms involved in chemical synaptic transmission. In this set of experiments we determined that h-tau42 produces a rapid failure in exocytosis. Our results also indicate that h-tau42 has previously unknown physiological properties that may be relevant in tau related neurodegenerative process.</p>
      <sec>
        <title>Human tau-42 acutely blocks chemical synaptic transmission without affecting the presynaptic calcium currents or the endocytic pathway</title>
        <p>The data presented here indicate that an excess of h-tau42 protein produces synaptic transmission block by interfering with a mechanism of synaptic vesicle exocytosis. Our conclusion, that h-tau42 induces a failure in neurotransmitter availability due to reduced synaptic vesicle release, is derived from morphological (Figures <xref ref-type="fig" rid="F4">4</xref>B,C), high frequency stimulation (Figure <xref ref-type="fig" rid="F1">1</xref>C), and spontaneous neurotransmitter release data (Figure <xref ref-type="fig" rid="F1">1</xref>E). Moreover, all the h-tau-42 injected synapses demonstrated a drastic block of both spontaneous and evoked transmitted release, without affecting presynaptic spike generation (Figure <xref ref-type="fig" rid="F1">1</xref>A) or the associated calcium current (Figure <xref ref-type="fig" rid="F1">1</xref>F). We interpret these findings as reflecting the reduced vesicle count at the active zone, the vesicles being instead concentrated in groups away from the active zone. It was also noted that these electron dense vesicular congregations were characterized by profiles resembling vesicular adhesions to microfilaments as would be expected if synapsin 1 were to be dephosphorylated affording a strong adhesion to such microfilaments (Llinas et al., <xref ref-type="bibr" rid="B20">1985</xref>). As a result h-tau42 would lead to the failure in exocytosis due to both a defect in the release mechanism and a reduction in vesicular availability (Llinas et al., <xref ref-type="bibr" rid="B19">1991</xref>).</p>
      </sec>
      <sec>
        <title>Human tau is phosphorylated in the isolated presynaptic terminal and induces abnormal vesicular clustering</title>
        <p>Previous experiments in drosophila have shown that misexpression of human &#x2013; tau (h-tau), the same isoform as the one used in our experiments, produced significant neurodegeneration (Jackson et al., <xref ref-type="bibr" rid="B11">2002</xref>; Avila et al., <xref ref-type="bibr" rid="B2">2004</xref>; Steinhilb et al., <xref ref-type="bibr" rid="B35">2007</xref>). In the drosophila model tau co-expressed with Shaggy, which generated a single fly homolog of GSK-3&#x3B2;, the phenotype was aggravated (Jackson et al., <xref ref-type="bibr" rid="B11">2002</xref>). Dysfunctional phenotypes were also found in the central neurons of lamprey, where long-term expression (2&#x2013;38&#x2009;days) of several h-tau isoforms produced neurodegenerative changes as a result of accumulation of h-hyperphosphorylated tau which correlated with the appearance of structures that resemble AD characteristic &#x2013; &#x201C;straight like filaments&#x201D; (Hall et al., <xref ref-type="bibr" rid="B8">1997</xref>). In the latter experiments the isoform hyperphosphorylated moiety was, to a larger extent, the long form of h-tau (h-tau42; Hall et al., <xref ref-type="bibr" rid="B8">1997</xref>; Lee et al., <xref ref-type="bibr" rid="B16">2009</xref>). It has been proposed that the physiological function of tau is adversely affected by excess phosphorylation resulting in tau being displaced from microtubules and aggregating, which in turn leads to microtubule disassembly, disruption of axonal transport, and finally synaptic failure (Stamer et al., <xref ref-type="bibr" rid="B34">2002</xref>).</p>
        <p>Concerning cephalopods, it has been demonstrated that h-tau binds to the squid axonal microtubules, but monomeric h-tau did not affect fast axonal transport (FAT), while filamentous h-tau42 did block anterograde FAT (LaPointe et al., <xref ref-type="bibr" rid="B15">2009</xref>). However, other studies have found that flies misexpressing tau show defects in neuronal traffic without evidence of tau aggregation (Jackson et al., <xref ref-type="bibr" rid="B11">2002</xref>; Mudher et al., <xref ref-type="bibr" rid="B26">2004</xref>). Finally, extracellular applied h-tau42 to cell cultures produced aberrant signaling through muscarinic receptor activation (Gomez-Ramos et al., <xref ref-type="bibr" rid="B7">2008</xref>; Diaz-Hernandez et al., <xref ref-type="bibr" rid="B5">2010</xref>), suggesting that even &#x201C;normal&#x201D; tau may be detrimental when its expression becomes elevated or when it accumulates extracellularly. From these observations, it appears that an optimal level of tau phosphorylation is required to achieve the balance in the level of &#x201C;free&#x201D; and &#x201C;microtubule bound&#x201D; tau that is essential in maintaining microtubule dynamics and subsequent axonal transport.</p>
        <p>As in the experiments mentioned above, in our experiments h-tau42 also became phosphorylated in the isolated axon (separated from the cell body) as demonstrated by immunohistochemistry using AT8 antibodies (Figure <xref ref-type="fig" rid="F3">3</xref>B). AT8 recognizes epitopes phosphorylated by GSK3 and cdk5 kinases both of which are found in squid axoplasm (Takahashi et al., <xref ref-type="bibr" rid="B36">1995</xref>; Morfini et al., <xref ref-type="bibr" rid="B25">2002</xref>; Hanger et al., <xref ref-type="bibr" rid="B9">2009</xref>), suggesting that either one or both kinases may be involved in the effects of h-tau42 in the presynaptic terminal. Whichever the specific kinase, the results demonstrate that isolated axons have the complete machinery to produce local post translational modifications and that these changes may explain, in part, the detrimental effects of excessive &#x201C;normal tau&#x201D; on the function of the presynaptic terminal.</p>
        <p>Moreover, the vesicle clustering observed in h-tau42 injected synapses, resembled the effect of unphosphorylated synapsin 1 on synaptic vesicle (Jackson et al., <xref ref-type="bibr" rid="B11">2002</xref>). The fact that h-tau42 is phosphorylated intra-axonally and that unphosphorylated synapsin 1 restrains the vesicle pool to the cytoskeleton &#x2013; producing a decreased number of vesicles available for exocytosis was actually demonstrated some time ago (Llinas et al., <xref ref-type="bibr" rid="B20">1985</xref>).</p>
        <p>A possible explanation of our findings is that h-tau42 induces changes in the balance of kinases and phosphatases, perhaps influenced by the concentration of h-tau aggregates. We hypothesize that this could decrease the phosphorylated/dephosphorylated ratio in proteins involved in synaptic vesicle function, such as synapsin 1, which would result in a reduction in the available vesicles and ultimately synaptic transmission failure. Tau is phosphorylated by several protein kinases and this is balanced by protein phosphatases dephosphorylation. The potential kinases and phosphatases involved are so numerous that biochemical experiments dedicated to solve this issue are necessary. If this process were to involve also constitutive vesicular dynamics a secondary dying-back event (Moreno et al., <xref ref-type="bibr" rid="B24">2009</xref>) would results in the synaptic disconnection encountered in AD pathomorphology.</p>
      </sec>
      <sec>
        <title>Potential pharmacological targets of tau-mediated neuropathogenesis</title>
        <p>The present results identify the protective effect of systemic administration of T-817MA on h-tau42 mediated axonal/synaptic dysfunction as shown in Figures <xref ref-type="fig" rid="F1">1</xref>B,D, <xref ref-type="fig" rid="F2">2</xref>, and <xref ref-type="fig" rid="F3">3</xref>C. This finding is highly significant, as it has been demonstrated that reduction of endogenous tau in an AD mouse model, ameliorates amyloid beta induced neurodegeneration at several levels (Roberson et al., <xref ref-type="bibr" rid="B31">2007</xref>). Therefore, T-817MA has a potential to treat tau pathology. Addressing the mechanisms of T-817MA neuro-protection in relation to tau pathology remains to be elucidated. But the fact that both functional and biochemical h-tau42 induced abnormalities in the presynaptic axon are prevented/ameliorated by this compound is a fundamental initial step toward the identification of therapeutic candidates to treat tauopathies.</p>
      </sec>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>Our results indicate that h-tau42 affects synaptic release by modifying intracellular phosphorylation homeostasis as a resultant of the h-tau42 hyperphosphorylation. This dynamic change, we propose, leads to a marked reduction of synaptic vesicle availability, most probably due to the reduction of synapsin 1 phosphorylation, known to be a powerful modulator of synaptic release (Llinas et al., <xref ref-type="bibr" rid="B20">1985</xref>). Beyond affecting synaptic release the reduction of such vesicular fusion on constitutive vesicular dynamics would also result in a disconnection event ultimately generating a &#x201C;dying-back&#x201D; phenomenon (Stamer et al., <xref ref-type="bibr" rid="B34">2002</xref>; Pigino et al., <xref ref-type="bibr" rid="B30">2007</xref>; Serulle et al., <xref ref-type="bibr" rid="B33">2007</xref>). Systemic administration of T-817MA, a proposed neuro-protective agent, rescued tau-induced synaptic abnormalities, markedly reduced h-tau42 hyperphosphorylation and prevented synaptic vesicle clustering, as determine by ultrastructural analysis.</p>
    </sec>
    <sec>
      <title>Author Contributions</title>
      <p>Herman Moreno, Soonwook Choi, Eunah Yu, Mutsuyuki Sugimori, and Rodolfo R. Llin&#xE1;s designed research; Herman Moreno, Soonwook Choi, Eunah Yu, Jorge E. Moreira, Mutsuyuki Sugimori, and Rodolfo R. Llin&#xE1;s performed research; Herman Moreno, Soonwook Choi, Eunah Yu, Janaina Brusco, Jorge E. Moreira, Mutsuyuki Sugimori, and Rodolfo R. Llin&#xE1;s analyzed data; Herman Moreno and Jesus Avila implemented molecular biology, and Herman Moreno, Soonwook Choi, G.P., Jorge E. Moreira, Jesus Avila, Mutsuyuki Sugimori, and Rodolfo R. Llin&#xE1;s wrote the paper.</p>
    </sec>
    <sec>
      <title>Conflict of Interest Statement</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p content-type="acknowledgment">Grant sponsors: NIH AG027476 to Herman Moreno; NS13742/NS/NINDS/NIH HHS to RLl; FAPESP (Funda&#xE7;&#xE3;o de Amparo &#xE0; Pesquisa do Estado de S&#xE3;o Paulo, Brasil) projects 2009/01571-6 and CinAPSe 05/56447-7 to Jorge E. Moreira.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arancio</surname><given-names>O.</given-names></name><name><surname>Zhang</surname><given-names>H. P.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>C.</given-names></name><name><surname>Trinchese</surname><given-names>F.</given-names></name><name><surname>Puzzo</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Hegde</surname><given-names>A.</given-names></name><name><surname>Yan</surname><given-names>S. F.</given-names></name><name><surname>Stern</surname><given-names>A.</given-names></name><name><surname>Luddy</surname><given-names>J. S.</given-names></name><name><surname>Lue</surname><given-names>L. F.</given-names></name><name><surname>Walker</surname><given-names>D. G.</given-names></name><name><surname>Roher</surname><given-names>A.</given-names></name><name><surname>Buttini</surname><given-names>M.</given-names></name><name><surname>Mucke</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Schmidt</surname><given-names>A. M.</given-names></name><name><surname>Kindy</surname><given-names>M.</given-names></name><name><surname>Hyslop</surname><given-names>P. A.</given-names></name><name><surname>Stern</surname><given-names>D. M.</given-names></name><name><surname>Yan</surname><given-names>S. S.</given-names></name></person-group> (<year>2004</year>). <article-title>RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice</article-title>. <source>EMBO J.</source> <volume>23</volume>, <fpage>4096</fpage>&#x2013;<lpage>4105</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600415</pub-id><pub-id pub-id-type="pmid">15457210</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avila</surname><given-names>J.</given-names></name><name><surname>Lucas</surname><given-names>J. J.</given-names></name><name><surname>Perez</surname><given-names>M.</given-names></name><name><surname>Hernandez</surname><given-names>F.</given-names></name></person-group> (<year>2004</year>). <article-title>Role of tau protein in both physiological and pathological conditions</article-title>. <source>Physiol. Rev.</source> <volume>84</volume>, <fpage>361</fpage>&#x2013;<lpage>384</lpage><pub-id pub-id-type="pmid">15044677</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>W.</given-names></name><name><surname>Teperman</surname><given-names>J.</given-names></name><name><surname>Walton</surname><given-names>K. D.</given-names></name><name><surname>Hirata</surname><given-names>K.</given-names></name><name><surname>Sugimori</surname><given-names>M.</given-names></name><name><surname>Llinas</surname><given-names>R. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Oral administration of pharmacologically active substances to squid: a methodological description</article-title>. <source>Biol. Bull.</source> <volume>216</volume>, <fpage>1</fpage>&#x2013;<lpage>6</lpage><pub-id pub-id-type="pmid">19218487</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>E.</given-names></name><name><surname>Braak</surname><given-names>H.</given-names></name><name><surname>Mandelkow</surname><given-names>E. M.</given-names></name></person-group> (<year>1994</year>). <article-title>A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads</article-title>. <source>Acta Neuropathol.</source> <volume>87</volume>, <fpage>554</fpage>&#x2013;<lpage>567</lpage><pub-id pub-id-type="doi">10.1007/BF00293315</pub-id><pub-id pub-id-type="pmid">7522386</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Hernandez</surname><given-names>M.</given-names></name><name><surname>G&#xF3;mez-Ramos</surname><given-names>A.</given-names></name><name><surname>Rubio</surname><given-names>A.</given-names></name><name><surname>G&#xF3;mez-Villafuertes</surname><given-names>R.</given-names></name><name><surname>Naranjo</surname><given-names>J. R.</given-names></name><name><surname>Miras-Portugal</surname><given-names>M. T.</given-names></name><name><surname>Avila</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau</article-title>. <source>J. Biol. Chem.</source> <volume>285</volume>, <fpage>32539</fpage>&#x2013;<lpage>32548</lpage><pub-id pub-id-type="pmid">20634292</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>M.</given-names></name><name><surname>Jakes</surname><given-names>R.</given-names></name><name><surname>Vanmechelen</surname><given-names>E.</given-names></name></person-group> (<year>1995</year>). <article-title>Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205</article-title>. <source>Neurosci. Lett.</source> <volume>189</volume>, <fpage>167</fpage>&#x2013;<lpage>169</lpage><pub-id pub-id-type="pmid">7624036</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Ramos</surname><given-names>A.</given-names></name><name><surname>Diaz-Hernandez</surname><given-names>M.</given-names></name><name><surname>Rubio</surname><given-names>A.</given-names></name><name><surname>Miras-Portugal</surname><given-names>M. T.</given-names></name><name><surname>Avila</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells</article-title>. <source>Mol. Cell. Neurosci.</source> <volume>37</volume>, <fpage>673</fpage>&#x2013;<lpage>681</lpage><pub-id pub-id-type="pmid">18272392</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>G. F.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>G.</given-names></name></person-group> (<year>1997</year>). <article-title>Human tau becomes phosphorylated and forms filamentous deposits when overexpressed in lamprey central neurons in situ</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>94</volume>, <fpage>4733</fpage>&#x2013;<lpage>4738</lpage><pub-id pub-id-type="pmid">9114060</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanger</surname><given-names>D. P.</given-names></name><name><surname>Seereeram</surname><given-names>A.</given-names></name><name><surname>Noble</surname><given-names>W.</given-names></name></person-group> (<year>2009</year>). <article-title>Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease</article-title>. <source>Expert Rev. Neurother.</source> <volume>9</volume>, <fpage>1647</fpage>&#x2013;<lpage>1666</lpage><pub-id pub-id-type="doi">10.1586/ern.09.104</pub-id><pub-id pub-id-type="pmid">19903024</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>K.</given-names></name><name><surname>Yamaguchi</surname><given-names>H.</given-names></name><name><surname>Takamura</surname><given-names>Y.</given-names></name><name><surname>Takagi</surname><given-names>A.</given-names></name><name><surname>Fukushima</surname><given-names>T.</given-names></name><name><surname>Iwakami</surname><given-names>N.</given-names></name><name><surname>Saitoh</surname><given-names>A.</given-names></name><name><surname>Nakagawa</surname><given-names>M.</given-names></name><name><surname>Yamada</surname><given-names>T.</given-names></name></person-group> (<year>2005</year>). <article-title>A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons</article-title>. <source>J. Pharmacol. Exp. Ther.</source> <volume>314</volume>, <fpage>252</fpage>&#x2013;<lpage>259</lpage><pub-id pub-id-type="pmid">15798005</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>G. R.</given-names></name><name><surname>Wiedau-Pazos</surname><given-names>M.</given-names></name><name><surname>Sang</surname><given-names>T. K.</given-names></name><name><surname>Wagle</surname><given-names>N.</given-names></name><name><surname>Brown</surname><given-names>C. A.</given-names></name><name><surname>Massachi</surname><given-names>S.</given-names></name><name><surname>Geschwind</surname><given-names>D. H.</given-names></name></person-group> (<year>2002</year>). <article-title>Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila</article-title>. <source>Neuron</source> <volume>34</volume>, <fpage>509</fpage>&#x2013;<lpage>519</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(02)00706-7</pub-id><pub-id pub-id-type="pmid">12062036</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>T.</given-names></name><name><surname>Hong Nguyen</surname><given-names>P. T.</given-names></name><name><surname>Ho</surname><given-names>S. A.</given-names></name><name><surname>Tran</surname><given-names>A. H.</given-names></name><name><surname>Ono</surname><given-names>T.</given-names></name><name><surname>Nishijo</surname><given-names>H.</given-names></name></person-group> (<year>2009</year>). <article-title>T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-beta peptide</article-title>. <source>Br. J. Pharmacol.</source> <volume>157</volume>, <fpage>451</fpage>&#x2013;<lpage>463</lpage><pub-id pub-id-type="pmid">19371351</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowall</surname><given-names>N. W.</given-names></name><name><surname>Kosik</surname><given-names>K. S.</given-names></name></person-group> (<year>1987</year>). <article-title>Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease</article-title>. <source>Ann. Neurol.</source> <volume>22</volume>, <fpage>639</fpage>&#x2013;<lpage>643</lpage><pub-id pub-id-type="pmid">3122646</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaFerla</surname><given-names>F. M.</given-names></name><name><surname>Green</surname><given-names>K. N.</given-names></name><name><surname>Oddo</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Intracellular amyloid-beta in Alzheimer's disease</article-title>. <source>Nat. Rev. Neurosci.</source> <volume>8</volume>, <fpage>499</fpage>&#x2013;<lpage>509</lpage><pub-id pub-id-type="pmid">17551515</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaPointe</surname><given-names>N. E.</given-names></name><name><surname>Morfini</surname><given-names>G.</given-names></name><name><surname>Pigino</surname><given-names>G.</given-names></name><name><surname>Gaisina</surname><given-names>I. N.</given-names></name><name><surname>Kozikowski</surname><given-names>A. P.</given-names></name><name><surname>Binder</surname><given-names>L. I.</given-names></name><name><surname>Brady</surname><given-names>S. T.</given-names></name></person-group> (<year>2009</year>). <article-title>The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity</article-title>. <source>J. Neurosci. Res.</source> <volume>87</volume>, <fpage>440</fpage>&#x2013;<lpage>451</lpage><pub-id pub-id-type="pmid">18798283</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Jung</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>G.</given-names></name><name><surname>Hall</surname><given-names>G. F.</given-names></name></person-group> (<year>2009</year>). <article-title>Exonic point mutations of human tau enhance its toxicity and cause characteristic changes in neuronal morphology, tau distribution and tau phosphorylation in the lamprey cellular model of tauopathy</article-title>. <source>J. Alzheimers Dis.</source> <volume>16</volume>, <fpage>99</fpage>&#x2013;<lpage>111</lpage><pub-id pub-id-type="pmid">19158426</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>V. M.</given-names></name><name><surname>Goedert</surname><given-names>M.</given-names></name><name><surname>Trojanowski</surname><given-names>J. Q.</given-names></name></person-group> (<year>2001</year>). <article-title>Neurodegenerative tauopathies</article-title>. <source>Annu. Rev. Neurosci.</source> <volume>24</volume>, <fpage>1121</fpage>&#x2013;<lpage>1159</lpage><pub-id pub-id-type="pmid">11520930</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J. W.</given-names></name><name><surname>Sugimori</surname><given-names>M.</given-names></name><name><surname>Llinas</surname><given-names>R. R.</given-names></name><name><surname>McGuinness</surname><given-names>T. L.</given-names></name><name><surname>Greengard</surname><given-names>P.</given-names></name></person-group> (<year>1990</year>). <article-title>Effects of synapsin I and calcium/calmodulin-dependent protein kinase II on spontaneous neurotransmitter release in the squid giant synapse</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>87</volume>, <fpage>8257</fpage>&#x2013;<lpage>8261</lpage><pub-id pub-id-type="pmid">1978321</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llinas</surname><given-names>R.</given-names></name><name><surname>Gruner</surname><given-names>J. A.</given-names></name><name><surname>Sugimori</surname><given-names>M.</given-names></name><name><surname>McGuinness</surname><given-names>T. L.</given-names></name><name><surname>Greengard</surname><given-names>P.</given-names></name></person-group> (<year>1991</year>). <article-title>Regulation by synapsin I and Ca(2+)-calmodulin-dependent protein kinase II of the transmitter release in squid giant synapse</article-title>. <source>J. Physiol.</source> <volume>436</volume>, <fpage>257</fpage>&#x2013;<lpage>282</lpage><pub-id pub-id-type="pmid">1676419</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llinas</surname><given-names>R.</given-names></name><name><surname>McGuinness</surname><given-names>T. L.</given-names></name><name><surname>Leonard</surname><given-names>C. S.</given-names></name><name><surname>Sugimori</surname><given-names>M.</given-names></name><name><surname>Greengard</surname><given-names>P.</given-names></name></person-group> (<year>1985</year>). <article-title>Intraterminal injection of synapsin I or calcium/calmodulin-dependent protein kinase II alters neurotransmitter release at the squid giant synapse</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>82</volume>, <fpage>3035</fpage>&#x2013;<lpage>3039</lpage><pub-id pub-id-type="pmid">2859595</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llin&#xE1;s</surname><given-names>R.</given-names></name><name><surname>Sugimori</surname><given-names>M.</given-names></name><name><surname>Lang</surname><given-names>E. J.</given-names></name><name><surname>Morita</surname><given-names>M.</given-names></name><name><surname>Fukuda</surname><given-names>M.</given-names></name><name><surname>Ninobe</surname><given-names>M.</given-names></name><name><surname>Mikoshiba</surname><given-names>K.</given-names></name></person-group> (<year>1994</year>). <article-title>The inositol high-polyphosphate series blocks synaptic transmission by preventing vesiculat fusion: a squid giant synapse study</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>91</volume>, <fpage>12990</fpage>&#x2013;<lpage>12993</lpage><pub-id pub-id-type="pmid">7809161</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname><given-names>J.</given-names></name></person-group> (<year>2007</year>). <article-title>Alzheimer's disease. A new take on tau</article-title>. <source>Science</source> <volume>316</volume>, <fpage>1416</fpage>&#x2013;<lpage>1417</lpage><pub-id pub-id-type="doi">10.1126/science.316.5830.1416</pub-id><pub-id pub-id-type="pmid">17556561</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micheva</surname><given-names>K. D.</given-names></name><name><surname>Smith</surname><given-names>S. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Array tomography: a new tool for imaging the molecular architecture and ultrastructure of neural circuits</article-title>. <source>Neuron</source> <volume>55</volume>, <fpage>25</fpage>&#x2013;<lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.06.014</pub-id><pub-id pub-id-type="pmid">17610815</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>E.</given-names></name><name><surname>Pigino</surname><given-names>G.</given-names></name><name><surname>Hernandez</surname><given-names>A. I.</given-names></name><name><surname>Kim</surname><given-names>N.</given-names></name><name><surname>Moreira</surname><given-names>J. E.</given-names></name><name><surname>Sugimori</surname><given-names>M.</given-names></name><name><surname>Llin&#xE1;s</surname><given-names>R. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Synaptic transmission block by presynaptic injection of oligomeric amyloid beta</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>106</volume>, <fpage>5901</fpage>&#x2013;<lpage>5906</lpage><pub-id pub-id-type="pmid">19304802</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morfini</surname><given-names>G.</given-names></name><name><surname>Szebenyi</surname><given-names>G.</given-names></name><name><surname>Elluru</surname><given-names>R.</given-names></name><name><surname>Ratner</surname><given-names>N.</given-names></name><name><surname>Brady</surname><given-names>S. T.</given-names></name></person-group> (<year>2002</year>). <article-title>Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility</article-title>. <source>EMBO J</source>. <volume>21</volume>, <fpage>281</fpage>&#x2013;<lpage>293</lpage><pub-id pub-id-type="doi">10.1093/emboj/21.3.281</pub-id><pub-id pub-id-type="pmid">11823421</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mudher</surname><given-names>A.</given-names></name><name><surname>Shepherd</surname><given-names>D.</given-names></name><name><surname>Newman</surname><given-names>T. A.</given-names></name><name><surname>Mildren</surname><given-names>P.</given-names></name><name><surname>Jukes</surname><given-names>J. P.</given-names></name><name><surname>Squire</surname><given-names>A.</given-names></name><name><surname>Mears</surname><given-names>A.</given-names></name><name><surname>Drummond</surname><given-names>J. A.</given-names></name><name><surname>Berg</surname><given-names>S.</given-names></name><name><surname>MacKay</surname><given-names>D.</given-names></name><name><surname>Asuni</surname><given-names>A. A.</given-names></name><name><surname>Bhat</surname><given-names>R.</given-names></name><name><surname>Lovestone</surname><given-names>S.</given-names></name></person-group> (<year>2004</year>). <article-title>GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila</article-title>. <source>Mol. Psychiatry</source> <volume>9</volume>, <fpage>522</fpage>&#x2013;<lpage>530</lpage> [In English].<pub-id pub-id-type="pmid">14993907</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>P. T.</given-names></name><name><surname>Kimura</surname><given-names>T.</given-names></name><name><surname>Ho</surname><given-names>S. A.</given-names></name><name><surname>Tran</surname><given-names>A. H.</given-names></name><name><surname>Ono</surname><given-names>T.</given-names></name><name><surname>Nishijo</surname><given-names>H.</given-names></name></person-group> (<year>2007</year>). <article-title>Ameliorative effects of a neuroprotective agent, T-817MA, on place learning deficits induced by continuous infusion of amyloid-beta peptide (1-40) in rats</article-title>. <source>Hippocampus</source> <volume>17</volume>, <fpage>443</fpage>&#x2013;<lpage>455</lpage><pub-id pub-id-type="doi">10.1002/hipo.20281</pub-id><pub-id pub-id-type="pmid">17397046</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nixon</surname><given-names>R. A.</given-names></name><name><surname>Cataldo</surname><given-names>A. M.</given-names></name><name><surname>Paskevich</surname><given-names>P. A.</given-names></name><name><surname>Hamilton</surname><given-names>D. J.</given-names></name><name><surname>Wheelock</surname><given-names>T. R.</given-names></name><name><surname>Kanaley-Andrews</surname><given-names>L.</given-names></name></person-group> (<year>1992</year>). <article-title>The lysosomal system in neurons. Involvement at multiple stages of Alzheimer's disease pathogenesis</article-title>. <source>Ann. N. Y. Acad. Sci.</source> <volume>674</volume>, <fpage>65</fpage>&#x2013;<lpage>88</lpage><pub-id pub-id-type="pmid">1288372</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>M.</given-names></name><name><surname>Arrasate</surname><given-names>M.</given-names></name><name><surname>Montejo De Garcini</surname><given-names>E.</given-names></name><name><surname>Munoz</surname><given-names>V.</given-names></name><name><surname>Avila</surname><given-names>J.</given-names></name></person-group> (<year>2001</year>). <article-title>In vitro assembly of tau protein: mapping the regions involved in filament formation</article-title>. <source>Biochemistry</source> <volume>40</volume>, <fpage>5983</fpage>&#x2013;<lpage>5991</lpage><pub-id pub-id-type="doi">10.1021/bi002961w</pub-id><pub-id pub-id-type="pmid">11352733</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pigino</surname><given-names>G.</given-names></name><name><surname>Opalach</surname><given-names>K.</given-names></name><name><surname>Serulle</surname><given-names>Y.</given-names></name><name><surname>Moreira</surname><given-names>J. E.</given-names></name><name><surname>Sugimori</surname><given-names>M.</given-names></name><name><surname>Llinas</surname><given-names>R. R.</given-names></name><name><surname>Brady</surname><given-names>S. T.</given-names></name></person-group> (<year>2007</year>). <article-title>1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>104</volume>, <fpage>2442</fpage>&#x2013;<lpage>2447</lpage><pub-id pub-id-type="pmid">17287338</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberson</surname><given-names>E. D.</given-names></name><name><surname>Scearce-Levie</surname><given-names>K.</given-names></name><name><surname>Palop</surname><given-names>J. J.</given-names></name><name><surname>Yan</surname><given-names>F.</given-names></name><name><surname>Cheng</surname><given-names>I. H.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Gerstein</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>G. Q.</given-names></name><name><surname>Mucke</surname><given-names>L.</given-names></name></person-group> (<year>2007</year>). <article-title>Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model</article-title>. <source>Science</source> <volume>316</volume>, <fpage>750</fpage>&#x2013;<lpage>754</lpage><pub-id pub-id-type="doi">10.1126/science.1141736</pub-id><pub-id pub-id-type="pmid">17478722</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selkoe</surname><given-names>D. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Alzheimer's disease: genes, proteins, and therapy</article-title>. <source>Physiol. Rev.</source> <volume>81</volume>, <fpage>741</fpage>&#x2013;<lpage>766</lpage><pub-id pub-id-type="pmid">11274343</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serulle</surname><given-names>Y.</given-names></name><name><surname>Morfini</surname><given-names>G.</given-names></name><name><surname>Pigino</surname><given-names>G.</given-names></name><name><surname>Moreira</surname><given-names>J. E.</given-names></name><name><surname>Sugimori</surname><given-names>M.</given-names></name><name><surname>Brady</surname><given-names>S. T.</given-names></name><name><surname>Llinas</surname><given-names>R. R.</given-names></name></person-group> (<year>2007</year>). <article-title>1-Methyl-4-phenylpyridinium induces synaptic dysfunction through a pathway involving caspase and PKC&#x2202; enzymatic activities</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>104</volume>, <fpage>2437</fpage>&#x2013;<lpage>2441</lpage><pub-id pub-id-type="doi">10.1073/pnas.0611227104</pub-id><pub-id pub-id-type="pmid">17287339</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamer</surname><given-names>K.</given-names></name><name><surname>Vogel</surname><given-names>R.</given-names></name><name><surname>Thies</surname><given-names>E.</given-names></name><name><surname>Mandelkow</surname><given-names>E.</given-names></name><name><surname>Mandelkow</surname><given-names>E. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress</article-title>. <source>J. Cell Biol.</source> <volume>156</volume>, <fpage>1051</fpage>&#x2013;<lpage>1063</lpage><pub-id pub-id-type="doi">10.1083/jcb.200108057</pub-id><pub-id pub-id-type="pmid">11901170</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinhilb</surname><given-names>M. L.</given-names></name><name><surname>Dias-Santagata</surname><given-names>D.</given-names></name><name><surname>Fulga</surname><given-names>T. A.</given-names></name><name><surname>Felch</surname><given-names>D. L.</given-names></name><name><surname>Feany</surname><given-names>M. B.</given-names></name></person-group> (<year>2007</year>). <article-title>Tau phosphorylation sites work in concert to promote neurotoxicity in vivo</article-title>. <source>Mol. Biol. Cell</source> <volume>18</volume>, <fpage>5060</fpage>&#x2013;<lpage>5068</lpage><pub-id pub-id-type="pmid">17928404</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Amin</surname><given-names>N.</given-names></name><name><surname>Grant</surname><given-names>P.</given-names></name><name><surname>Pant</surname><given-names>H. C.</given-names></name></person-group> (<year>1995</year>). <article-title>P13suc1 associates with a cdc2-like kinase in a multimeric cytoskeletal complex in squid axoplasm</article-title>. <source>J. Neurosci.</source> <volume>15</volume>, <fpage>6222</fpage>&#x2013;<lpage>6229</lpage><pub-id pub-id-type="pmid">7666204</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshiyama</surname><given-names>Y.</given-names></name><name><surname>Higuchi</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>S. M.</given-names></name><name><surname>Iwata</surname><given-names>N.</given-names></name><name><surname>Saido</surname><given-names>T. C.</given-names></name><name><surname>Maeda</surname><given-names>J.</given-names></name><name><surname>Suhara</surname><given-names>T.</given-names></name><name><surname>Trojanowski</surname><given-names>J. Q.</given-names></name><name><surname>Lee</surname><given-names>V. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model</article-title>. <source>Neuron</source> <volume>53</volume>, <fpage>337</fpage>&#x2013;<lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.01.010</pub-id><pub-id pub-id-type="pmid">17270732</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
